Return to results
Journal articles (2020), Journal for ImmunoTherapy of Cancer, 8 (2), pp. e000648

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

Quinn Casey, Garrison Louis P, Pownell Anja K, Atkins Michael B, PUYOU DE POUVOURVILLE Gérard , Harrington Kevin, Ascierto Paolo Antonio, McEwan Phil, Wagner Samuel, Borrill John, Wu Elise

Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient’s immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and prolonged survival in some patients. However, providing robust evidence of the long-term benefits of IOs at health technology assessment (HTA) submission presents several challenges for manufacturers. The aim of this article was to identify, analyze, categorize, and further explore the key challenges that regulators, HTA agencies, and payers commonly encounter when assessing the long-term benefits of IO therapies. Insights were obtained from an international, multi-stakeholder steering committee (SC) and expert panels comprising of payers, economists, and clinicians. Link to the article

QUINN, C., GARRISON, L.P., POWNELL, A.K., ATKINS, M.B., PUYOU DE POUVOURVILLE, G., HARRINGTON, K. ... WU, E. (2020). Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. Journal for ImmunoTherapy of Cancer, 8(2), pp. e000648.